The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal ...
Explore the impact of drug discovery automation in 2026, addressing complexity and improving decision-making across ...
Utz Brands issued a business update ahead of the company's presentation this week at the ICR Conference. For Q4, Utz Brands ...
Bacterial Conjunctivitis Drugs Market is expected to reach US$ 4.9 Billion by 2036, Driven by Increasing Prevalence of Eye ...
CARROLLTON, GA, UNITED STATES, January 8, 2026 / EINPresswire.com / — ZYNC Announces 80% Revenue Growth in 2025 as Demand ...
Novamigra Therapeutics secures ~€3 million funding to advance first-in-human Phase 1 study of its migraine prophylaxis ...
The decline of linear TV, the stickiness of AI and the battle against misinformation are all on the menu for 2026.
Q2 2026 Earnings Call Transcript January 8, 2026 Tilray Brands, Inc. misses on earnings expectations. Reported EPS is $-0.41 ...
Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...
Serán Bioscience, LLC, in collaboration with leading developer and design-builder Mortenson, hosted a topping-out ceremony ...
Zacks Investment Research on MSN
Here's why you should retain Cencora stock in your portfolio now
Cencora, Inc. COR is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback